linagliptin / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 31 Diseases   34 Trials   34 Trials   1690 News 


«12345678910111213...1819»
  • ||||||||||  Victoza (liraglutide) / Novo Nordisk, Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, Trulicity (dulaglutide) / Eli Lilly
    The Dark Side of Semaglutide: Discrete Instances of Acalculous Cholecystitis and Acute Pancreatitis in the Same Patient Due to Continued Use of GLP-1 Agonist (Exhibit Hall) -  Jul 29, 2023 - Abstract #ACG2023ACG_607;    
    She was currently on linagliptin, insulin and metformin but requested to re-attempt semaglutide due to linagliptin costs and significant weight gain on insulin...It is important to accurately characterize the risk of adverse effects for patients prior to initiation. For patients without obvious risk factors for gallbladder or pancreatic disease, this task is significantly more difficult and there should be a low threshold to identify these medications as the culprit when there is no more glaring explanation.
  • ||||||||||  Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
    Trial completion:  Replication of the CARMELINA Diabetes Trial in Healthcare Claims (clinicaltrials.gov) -  Jul 27, 2023   
    P=N/A,  N=101830, Completed, 
    For patients without obvious risk factors for gallbladder or pancreatic disease, this task is significantly more difficult and there should be a low threshold to identify these medications as the culprit when there is no more glaring explanation. Unknown status --> Completed
  • ||||||||||  Long-term insulin independence following allogenic islet transplant and childbirth (Indigo H) -  Jul 7, 2023 - Abstract #IPITAIXACTRMS2023IPITA_IXA_CTRMS_415;    
    5y post-IT and 7y PP with only oral DM medication support. While pregnancy in T1D and immunosuppression remains high risk, this suggests that successful childbirth post-IT can be safely achieved without significantly compromising graft function.
  • ||||||||||  Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
    A Case of Wolf () -  Jul 3, 2023 - Abstract #WCD2023WCD_5020;    
    She had been started on linagliptin 5 months prior to the occurrence of the blisters...However, unlike in our case, the distribution of blisters in previously reported cases was not confined to psoriatic skin. Advancements in the understanding of the pathogenesis of psoriasis vulgaris may shed light onto the differing distribution of subsequent bullous pemphigoid eruptions
  • ||||||||||  Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
    New P3 trial:  D (clinicaltrials.gov) -  Jun 2, 2023   
    P3,  N=597, Not yet recruiting, 
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    New P4 trial:  SEMA-VR: Semaglutide and Vascular Regeneration (clinicaltrials.gov) -  May 23, 2023   
    P4,  N=100, Recruiting, 
  • ||||||||||  Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim
    Treating Pheochromocytoma for Glycemic and Blood Pressure Control (ENDOExpo) -  May 11, 2023 - Abstract #ENDO2023ENDO_1933;    
    Her medical regimen consisted of linagliptin 5mg daily, metformin 1000mg twice daily, insulin glargine 40 units daily, losartan 50mg twice daily, amlodipine 10mg daily and hydrochlorothiazide 25mg daily...Additionally, UACR improved to 1352.94 mg/g and empagliflozin was added to avoid diabetic kidney progression...Detection of resistant HTN should had prompted earlier detection of pheochromocytoma in this patient. As physicians, we should be aware of endocrine causes of diabetes and HTN, such as Cushing syndrome, Acromegaly, Primary Aldosteronism, and Pheochromocytoma and Paraganglioma, as treating these may lead to better quality of life, and less disease-related complications and polypharmacy.
  • ||||||||||  Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, Olumiant (baricitinib) / Incyte, Eli Lilly, Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim
    Retrospective data, Journal:  Effects of albuminuria-lowering treatments on inflammation markers: A post hoc analysis from the ROTATE trials. (Pubmed Central) -  May 11, 2023   
    As physicians, we should be aware of endocrine causes of diabetes and HTN, such as Cushing syndrome, Acromegaly, Primary Aldosteronism, and Pheochromocytoma and Paraganglioma, as treating these may lead to better quality of life, and less disease-related complications and polypharmacy. No abstract available
  • ||||||||||  Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, Onglyza (saxagliptin) / AstraZeneca
    The Landscape of Pharmacogenetic Variants Associated with Noninsulin Antidiabetic Drugs in the Indian Population (Room 5; [Board No. 71]) -  Apr 10, 2023 - Abstract #ADA2023ADA_143;    
    We also predict an increased CYP2C19-mediated DDGI risk for CYP3A4/3A5-metabolized NIADs, saxagliptin, linagliptin and glyburide when co-administered with PPIs. Our findings provide an actionable resource for accelerating future diabetes PGx studies in Indians and reconsidering NIAD dosing guidelines to ensure maximum efficacy and safety in the population.
  • ||||||||||  Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
    Clinical, Journal:  Management of older hospitalized patients with type 2 diabetes using linagliptin: Lina-Older Study. (Pubmed Central) -  Mar 15, 2023   
    The assay results obtained by using the developed method were statistically compared to those obtained by the reported HPLC method, and a satisfying agreement was observed. The linagliptin-basal insulin regimen was an effective alternative with fewer hypoglycemic events and daily insulin injections than intensive basal-bolus insulin in very old patients with type 2 diabetes with mild-to-moderate hyperglycemia treated at home without injectable therapies.
  • ||||||||||  Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments. (clinicaltrials.gov) -  Feb 16, 2023   
    P=N/A,  N=5, Terminated, 
    This study provides evidence that both DPP-4 inhibition and sulfonylurea reverse T2D-induced BBB leakage which may contribute to the antidiabetic neurorestorative effects. N=50 --> 5 | Trial completion date: Jul 2022 --> Feb 2023 | Recruiting --> Terminated | Trial primary completion date: Jul 2021 --> Feb 2023; Recruitment too slow
  • ||||||||||  Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, Byetta (exenatide) / AstraZeneca
    Preclinical, Journal:  Exendin-4 and linagliptin attenuate neuroinflammation in a mouse model of Parkinson's disease. (Pubmed Central) -  Feb 8, 2023   
    pathway in a mouse model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Therefore, these two drugs may serve as novel anti-inflammatory treatments for Parkinson's disease.
  • ||||||||||  Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
    Preclinical, Journal:  Linagliptin treatment is associated with altered cobalamin (VitB12) homeostasis in mice and humans. (Pubmed Central) -  Jan 13, 2023   
    Linagliptin might inhibit the N-terminal degradation of the transcobalamin receptor CD320, which is necessary for uptake of Cbl into endothelial cells. Because we demonstrate that linagliptin led to increased organ levels of Cbl in mice, sustained constant medium MMA levels in humans, and inhibited CD320 processing by DPP-4 in-vitro, we speculate that linagliptin promotes intra-cellular uptake of Cbl by prolonging half-life of CD320.
  • ||||||||||  Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
    Journal:  Beta-endoproteolysis of the cellular prion protein by dipeptidyl peptidase-4 and fibroblast activation protein. (Pubmed Central) -  Dec 28, 2022   
    C2 levels relative to total PrP were reduced in several tissues from FAP-null mice, and, while knockout of DPP4 lacked an analogous effect, the combined DPP4/FAP inhibitor linagliptin, but not the FAP-specific inhibitor SP-13786, reduced C2 and total PrP levels in two murine cell-based models of prion infections. Thus, the net activity of the S9B peptidases FAP and DPP4 and their cognate inhibitors/modulators affect the physiology and pathogenic potential of PrP.